Skip to main content
. 2017 Jun 13;96(1):5–12. doi: 10.1159/000477345

Fig. 5.

Fig. 5

a, b The percentage of patients whose symptom scores decreased ≥50% compared with pretreatment scores at each observation point. Epigastric pain syndrome (EPS) symptom scores. The proportion of patients in the famotidine group with EPS symptoms was higher than that for the placebo group at all observation points. Postprandial distress syndrome (PDS) symptom scores.